• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

第二代表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌中的应用

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

作者信息

Sequist Lecia V

机构信息

Massachusetts General Hospital Cancer Center, 32 Fruit Street, Yawkey Suite 7B, Boston, Massachusetts 02114, USA.

出版信息

Oncologist. 2007 Mar;12(3):325-30. doi: 10.1634/theoncologist.12-3-325.

DOI:10.1634/theoncologist.12-3-325
PMID:17405897
Abstract

Inhibiting epidermal growth factor receptor (EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and clinical research within the field. Second-generation EGFR-targeted agents that aim to further improve patient outcomes are now in preclinical and clinical trials. This review discusses four promising agents that are currently being studied in NSCLC: EKB-569, HKI-272, CI-1033, and ZD6474.

摘要

抑制表皮生长因子受体（EGFR）信号传导已被证明是治疗非小细胞肺癌（NSCLC）患者的有效策略，为此目的开发的第一代药物吉非替尼和厄洛替尼，在该领域引发了生物学和临床研究的独特升级。旨在进一步改善患者预后的第二代EGFR靶向药物目前正处于临床前和临床试验阶段。本综述讨论了目前正在NSCLC中研究的四种有前景的药物：EKB-569、HKI-272、CI-1033和ZD6474。

相似文献

1
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.第二代表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌中的应用
Oncologist. 2007 Mar;12(3):325-30. doi: 10.1634/theoncologist.12-3-325.
2
An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.非小细胞肺癌二线和三线治疗中分子靶向治疗的最新进展：聚焦 EGFR 抑制剂和抗血管生成药物。
Clin Transl Oncol. 2013 May;15(5):343-57. doi: 10.1007/s12094-012-0964-2. Epub 2013 Jan 29.
3
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.使用非易瑞沙表皮生长因子受体酪氨酸激酶抑制剂的临床研究。
Lung Cancer. 2003 Aug;41 Suppl 1:S43-8. doi: 10.1016/s0169-5002(03)00141-7.
4
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
5
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.表皮生长因子受体抑制在局部晚期非小细胞肺癌综合治疗中的应用
Semin Oncol. 2005 Apr;32(2 Suppl 3):S35-41. doi: 10.1053/j.seminoncol.2005.03.008.
6
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.ZD6474（一种表皮生长因子受体和血管内皮生长因子受体的小分子激酶抑制剂）用于经治晚期非小细胞肺癌的II期数据。
Clin Lung Cancer. 2005 Sep;7(2):89-91. doi: 10.1016/S1525-7304(11)70394-1.
7
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
8
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?对于具有EGFR突变的非小细胞肺癌患者，应推荐哪种酪氨酸激酶抑制剂作为初始治疗？
Med Oncol. 2014 Aug;31(8):78. doi: 10.1007/s12032-014-0078-5. Epub 2014 Jun 24.
9
Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.第二代表皮生长因子酪氨酸激酶抑制剂在非小细胞肺癌中的应用
Expert Opin Investig Drugs. 2009 Mar;18(3):293-301. doi: 10.1517/13543780902762843.
10
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.ZD6474是一种血管内皮生长因子受体酪氨酸激酶抑制剂，在非小细胞肺癌模型中可抑制实验性肺转移的生长及恶性胸腔积液的产生。
Oncol Res. 2006;16(1):15-26. doi: 10.3727/000000006783981260.

引用本文的文献

1
Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials.厄洛替尼在多种癌症中的多方面作用：纳米技术干预、专利全景及临床试验进展。
Med Oncol. 2024 Jun 12;41(7):173. doi: 10.1007/s12032-024-02414-5.
2
Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer.基于酪氨酸激酶抑制剂的纳米疗法用于表皮生长因子受体耐药非小细胞肺癌的最新进展
Curr Drug Deliv. 2025;22(3):249-260. doi: 10.2174/0115672018278617231207051907.
3
HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.
HER特异性酪氨酸激酶抑制剂通过STAT5和JNK的参与对乳腺癌细胞系发挥其抗肿瘤作用。
PLoS One. 2016 Jan 6;11(1):e0146311. doi: 10.1371/journal.pone.0146311. eCollection 2016.
4
Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.不可逆性表皮生长因子受体（ErbB）家族阻滞剂阿法替尼在经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）预处理的伴有脑转移或软脑膜疾病的非小细胞肺癌患者中的疗效。
J Thorac Oncol. 2015 Jan;10(1):156-63. doi: 10.1097/JTO.0000000000000380.
5
Personalized prediction of EGFR mutation-induced drug resistance in lung cancer.肺癌中 EGFR 突变诱导耐药的个体化预测。
Sci Rep. 2013 Oct 4;3:2855. doi: 10.1038/srep02855.
6
In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features.基于新型骨架的表皮生长因子受体-苏氨酸790甲硫氨酸（EGFR-T790M）抑制剂的计算机虚拟鉴定：从共同特征提取开始。
Drug Des Devel Ther. 2013 Aug 14;7:789-839. doi: 10.2147/DDDT.S41305. eCollection 2013.
7
Irreversible EGFR inhibitor EKB-569 targets low-LET γ-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma.不可逆的 EGFR 抑制剂 EKB-569 靶向低 LET γ 射线触发的 REL 调控，并增强鳞状细胞癌中的细胞死亡。
PLoS One. 2011;6(12):e29705. doi: 10.1371/journal.pone.0029705. Epub 2011 Dec 29.
8
Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors.克服表皮生长因子受体家族酪氨酸激酶抑制剂耐药的策略。
Cancer Treat Rev. 2011 Oct;37(6):456-64. doi: 10.1016/j.ctrv.2011.01.003. Epub 2011 Mar 1.
9
Lung cancer therapeutics that target signaling pathways: an update.靶向信号通路的肺癌治疗药物：最新进展。
Expert Rev Respir Med. 2010 Oct;4(5):631-45. doi: 10.1586/ers.10.64.
10
Perspectives: Other ErbB2-Targeted Therapies.观点：其他靶向ErbB2的疗法。
Breast Care (Basel). 2010;5(s1):25-27. doi: 10.1159/000285779. Epub 2010 Apr 26.